Idiopathic Pulmonary Fibrosis — Research Summary
Printed from RareWays (rareways.com.au) on 10 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Association between smoking and prognosis in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Kim Kyeongmin et al. — Pulmonology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42339520/
- 2.
Evaluating prognostic value of the prognostic nutritional index, CRP-to-albumin ratio and lymphocyte-to-CRP ratio in patients with idiopathic pulmonary fibrosis.
Zhang Qing et al. — Annals of medicine (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42363640/
- 3.
Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE).
Lang David et al. — Annals of medicine (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41852279/
- 4.
Ophiopogon japonicus alleviates pulmonary fibrosis through modulation of HIF1A/TUBB3 axis-associated M2 macrophage polarization and arginine metabolic alterations.
Wen Kehan et al. — Journal of ethnopharmacology (15 November 2026)
https://pubmed.ncbi.nlm.nih.gov/42285238/
- 5.
Multi-omics reveals the effects and mechanisms of Xinxue Granules against idiopathic pulmonary fibrosis through activating the cAMP/EPAC/CREB axis.
Zhang Xia et al. — Journal of ethnopharmacology (15 November 2026)
https://pubmed.ncbi.nlm.nih.gov/42302945/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Recruiting — Phase 2 — AstraZeneca
https://clinicaltrials.gov/study/NCT07652658
- 2.
A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants
Recruiting — Phase 1 — Endeavor Biomedicines, Inc.
https://clinicaltrials.gov/study/NCT07454291
- 3.
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
Recruiting — Phase 2 — Avalyn Pharma Inc.
https://clinicaltrials.gov/study/NCT07194382
- 4.
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
Recruiting — Phase 3 — Boehringer Ingelheim
https://clinicaltrials.gov/study/NCT07201922
- 5.
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Recruiting — Phase 2 — Rein Therapeutics
https://clinicaltrials.gov/study/NCT06968845
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease in which scar tissue builds up in the lungs, making breathing increasingly difficult. The cause is unknown and it predominantly affects adults over 50. Three antifibrotic medicines can slow progression, and research into new treatments is advancing rapidly. An estimated 8,500 Australians live with IPF.
Most Recent Research
BACKGROUND: Although smoking is a well-established risk factor for idiopathic pulmonary fibrosis (IPF) development, its impact on clinical outcomes remains unclear. RESEARCH QUESTION: Is smoking associated with clinical outcomes of IPF? METHODS: A systematic search of PubMed, Embase, and the Cochrane Library was conducted to identify studies reporting associations between smoking status and IPF outcomes, including mortality, acute exacerbation (AE), lung cancer development, and baseline lung function. Summary estimates with 95% confidence intervals (CIs) were pooled using random-effects model. Subgroup analyses were conducted by study region. RESULTS: Forty-nine studies comprising 32 974 patients were included. Overall mortality did not differ by smoking status. However, significant regional differences were observed, with ever smokers demonstrating higher mortality in non - East Asian studies (Hazard ratio [HR] 1.17, 95% CI: 1.03-1.33) but lower mortality in East Asian studies (HR 0.75, 95% CI: 0.62-0.91, p-for-interaction < 0.001) compared with never smokers. Current smokers had a higher risk of developing lung cancer compared with non-current smokers (HR 1.88, 95% CI: 1.24-2.87). No significant associations were observed between smoking and the risk of AEs or baseline forced vital capacity. CONCLUSION: Smoking was not associated with overall mortality in IPF, although significant regional differences were observed.
Common Questions
What is Idiopathic Pulmonary Fibrosis?
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease in which scar tissue builds up in the lungs, making breathing increasingly difficult. The cause is unknown and it predominantly affects adults over 50. Three antifibrotic medicines can slow progression, and research into new treatments is advancing rapidly. An estimated 8,500 Australians live with IPF.
How many clinical trials are available for Idiopathic Pulmonary Fibrosis?
RareWays currently indexes 697 clinical trials for Idiopathic Pulmonary Fibrosis, of which 126 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Idiopathic Pulmonary Fibrosis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Idiopathic Pulmonary Fibrosis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.